Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by gebremeskelon Mar 19, 2024 4:02pm
114 Views
Post# 35941515

RE:RE:RE:Gate Keeper ?

RE:RE:RE:Gate Keeper ?There has been no negative news but according to Mr. Seto, the 90 patient enrolment milestone was expected to be a major catalyst and it simply wasn't.

I think the drop was because of disappointed expectations. Nothing negative was announced - Baxter maintained distribution rights, the trial is continuing as before and Dr. Kellum is very pleased with the results as before.

But Baxter chose not to look at the raw data and it doesn't seem we will get any results update until the end of the trial.

So...nothing to see here yet. 

Upcoming catalysts will be the Vantive launch, (or Baxter sell off of it's Kidney Care business). a projected Tigris completion by the end of 2024 and approval and the start of commercialization by the end of 2025.

There is also the possibility of a buyout by Baxter, Vantive or somebody else. But this is just speculation.

So there may be no dramatic sp action in the near term and those who got in with the expectation of significant sp appreciation are falling away and the sp is settling back down to it's previous comfort level.

Accountprince wrote: Gerry you are on the right track. While the Three Stooges were demonstrating their Stoopidity the price was manipulated down to .40. There has been no negative news yet we're down by .27 per share since we hit interim of 90 patients. What logic is there to support that drop? Three incoherent flunkies foaming nonsense at the mouth? Or an orchestrated program to bring it down while the fools attempt to cover?

how can success result in a 40% decline in the share price?  How can a single respected poster get thrown out for no reason and for nothing done in the last five years? Hoping to be wrong but it happens when the intent is to issue cheap shares to friends and family. Even worse when you issue cheap options to management and those who are supposed to be governance. If anything issued below the .67 a share that proves my assertion. EOM


<< Previous
Bullboard Posts
Next >>